Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours. (19th December 2022)

• Record Type: Journal Article
• Authors: Li, Yuehua; Wei, Chengjiang; Wang, Wei; Li, Qingfeng; Wang, Zhi‐Chao
• Is Part Of: Journal of pathology. Volume 9:Number 2(2023)
• Page Start: 89
• Page End: 99
• Publication Date: 2022-12-19
• Subjects: TrkB -- tyrosine kinase -- NTRK -- abnormal activation -- gene fusion -- neurogenic tumours -- targeted therapy; Pathology -- Periodicals; Diagnosis, Laboratory -- Periodicals; 616.07
• DOI: 10.1002/cjp2.307
• Languages: English
• ISSNs: 2056-4538

Abstract

Abstract: Tropomyosin receptor kinase B (TrkB), a transmembrane receptor protein, has been found to play a pivotal role in neural development. This protein is encoded by the neurotrophic receptor tyrosine kinase 2 ( NTRK2 ) gene, and its abnormal activation caused by NTRK2 overexpression or fusion can contribute to tumour initiation, progression, and resistance to therapeutics in multiple types of neurogenic tumours. Targeted therapies for this mechanism have been designed and developed in preclinical and clinical studies, including selective TrkB inhibitors and pan‐TRK inhibitors. This review describes the gene structure, biological function, abnormal TrkB activation mechanism, and current‐related targeted therapies in neurogenic tumours.